Skip to main content

Table 2 Tumor response and outcomes of the 92 patients

From: Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma

  CCRT (n = 25) Chemotherapy (n = 67) p-value
Capecitabine plus cisplatin chemotherapy, total cycles (mean ± SD) 5.6 ± 5.8 4.0 ± 3.2 0.082
Tumor response (n = 90), n (%)    0.365
 CR 0 (0) 0 (0)  
 PR 1 (4.0) 3 (4.6)  
 SD 13 (52.0) 24 (36.9)  
 PD 11 (44.0) 38 (58.5)  
 Disease-control rate (CR + PR + SD) 14 (56.0) 27 (41.5) 0.217
Median FU duration, months (IQR) 7.4 (4.1 – 15.1) 4.1 (2.3 – 8.3) 0.044
Median PFS, months (95% CI) 4.3 (3.3 – 5.4) 1.9 (1.3 – 2.4) 0.001*
Median OS, months (95% CI) 9.3 (7.6 – 11.0) 6.2 (4.1 – 8.2) 0.162*
  1. *By log-rank test.